Document is current
Any future updates will be listed below
-
Authors
Sengupta, Raj https://orcid.org/0000-0002-9720-0396
Machado, Pedro M. https://orcid.org/0000-0002-8411-7972
Goupille, Philippe https://orcid.org/0000-0002-8605-1567
Rudwaleit, Martin https://orcid.org/0000-0001-5445-548X
Sheesh, Mohamed https://orcid.org/0009-0008-4430-9399
Ng, Khai Jing
Ngantcha, Marcus
Yan, Yan
Russ, Hagen https://orcid.org/0009-0006-2743-1398
Doridot, Gabriel
Xue, Yu
Poddubnyy, Denis https://orcid.org/0000-0002-4537-6015
Baraliakos, Xenofon https://orcid.org/0000-0002-9475-9362
Navarro-Compán, Victoria https://orcid.org/0000-0002-4527-852X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02696785 at ClinicalTrials.govnct04285229 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
OP0046 EFFECT OF IXEKIZUMAB TREATMENT ON MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS; A POST-HOC ANALYSIS OF A PLACEBO AND ACTIVE CONTROLLED RCT
https://doi.org/10.1136/annrheumdis-2024-eular.602
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (Results)
https://doi.org/10.1136/annrheumdis-2019-216118
POS0909 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS IN PATIENTS IRRESPECTIVE OF HLA-B27 STATUS: POOLED RESULTS FROM THE COAST-V AND COAST-W TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.801
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2024-004429
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
FRI0420 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SF-36 RESULTS OF TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1237
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
https://doi.org/10.1007/s40744-025-00810-5
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS)
https://doi.org/10.1136/annrheumdis-2019-eular.1236
THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2053
AB0710 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH AS MEASURED BY SF-36 IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS NAIVE TO BIOLOGICAL THERAPY: 52 WEEK RESULTS OF A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1612
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2021-001839
Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III Trials
https://doi.org/10.1007/s40744-026-00862-1
POS0915 SUSTAINABILITY OF IXEKIZUMAB RESPONSE AT THE INDIVIDUAL PATIENT LEVEL OVER TIME IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1340
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1466
POS0901 IXEKIZUMAB SHOWS A DISTINCT PATTERN OF PAIN IMPROVEMENT BEYOND INFLAMMATION IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.211
AB0868 HOW DO EARLY DISEASE ACTIVITY AND EARLY CLINICAL RESPONSE ASSOCIATE WITH LONG-TERM OUTCOMES WITH IXEKIZUMAB IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS?
https://doi.org/10.1136/annrheumdis-2024-eular.623
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
POS0908 EFFICACY OF IXEKIZUMAB THROUGH 52 WEEKS FOR IMPROVING PERIPHERAL JOINT INVOLVEMENT AMONG PATIENTS WITH RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.761
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
POS0931 EFFICACY AND IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AT WEEKS 16 AND 52 IN IXEKIZUMAB TREATED BIOLOGICAL NAÏVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ACHIEVING CLINICALLY IMPORTANT PAIN AT NIGHT REDUCTION AT WEEK 16: RESULTS FROM COAST-V TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.169
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
OP0238 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1613
FRI0400 LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS/ANKYLOSING SPONDYLITIS: AN INTEGRATED ANALYSIS OF COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1232
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
Documents that mention this clinical trial
POS0801 IXEKIZUMAB IMPROVES DISEASE ACTIVITY OF RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS IN CHINESE PATIENTS IRRESPECTIVE OF BASELINE OBJECTIVE INFLAMMATION STATUS
https://doi.org/10.1136/annrheumdis-2024-eular.357
Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level
https://doi.org/10.1007/s40744-025-00765-7
AB0912 IXEKIZUMAB IMPROVES SPINAL PAIN, STIFFNESS, FUNCTION, AND MOBILITY OF RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS IN CHINESE PATIENTS REGARDLESS OF BASELINE INFLAMMATION STATUS
https://doi.org/10.1136/annrheumdis-2024-eular.2412
Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III Trials
https://doi.org/10.1007/s40744-026-00862-1
Rapid and Sustained Effect of Ixekizumab on Patient Global, Spinal Pain, Stiffness, and Fatigue in Chinese Patients with Radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-024-00688-9
Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging
https://doi.org/10.1007/s40744-025-00819-w
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 27 February 2026
Accepted: 15 May 2026
First Online: 2 June 2026
Declarations
Conflict of Interest: Raj Sengupta has received speaking fees form AbbVie, UCB, Novartis, Eli Lilly and Company, and Pfizer and has received research support from Novartis and UCB. Pedro M. Machado has received speaking fees from AbbVie, BMS, Celgene, Eli Lilly and Company, Galapagos/Alfasigma, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, and consulting fees form AbbVie, BMS, Celgene, Eli Lilly and Company, Galapagos/Alfasigma, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB. Philippe Goupille has received speaking fees from AbbVie, Amgen, BMS, Celltrion, Chugai, Janssen, Eli Lilly and Company, MSD, Novartis and UCB, and consulting fees from AbbVie, Janssen, Eli Lilly and Company, MSD, Novartis and UCB. Martin Rudwaleit has received speaking fees from AbbVie, AstraZeneca, Janssen, Eli Lilly and Company, Novartis, and UCB, and consulting fees from AbbVie, AstraZeneca, Janssen, Eli Lilly and Company, Novartis, and UCB, and has received grant/research support from Janssen and UCB. Yu Xue has no conflict to declare. Denis Poddubnyy has received research support from AbbVie, Eli Lilly, MSD, Novartis, Pfizer, consulting fees from AbbVie, Biocad, Bristol-Myers Squibb, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer, and UCB, speaking fees from AbbVie, Canon, DKSH, Eli Lilly, Janssen, MSD, Medscape, Novartis, Peervoice, Pfizer, and UCB, and is a member of the executive committee of ASAS. Xenofon Baraliakos has received speaking fees from Alfasigma, Amgen, BMS, Cesas, Celltrion, Galapagos, Janssen, Eli Lilly and Company, Moonlake, Novartis, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB and Zuellig, consulting fees from AbbVie, Alfasigma, Amgen, BMS, Cesas, Celltrion, Galapagos, Janssen, Eli Lilly and Company, Moonlake, Novartis, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB and Zuellig and research support from AbbVie, Celltrion, Janssen and Moonlake. Victoria Navarro-Compán has received speaking fees from AbbVie, Fresenius Kabi, Janssen, Eli Lilly and Company, Novartis, Pfizer, and UCB, consulting fees from AbbVie, Alfasigma, Galapagos, Eli Lilly and Company, Novartis, Pfizer and UCB, and research support from Novartis and ASAS. Mohamed Sheesh, Khai Jing Ng, Marcus Ngantcha, Yan Yan, Hagen Russ, and Gabriel Doridot are all employees and minor shareholders of Eli Lilly and Company.
Ethical Approval: This post hoc analysis was conducted using data from COAST-V and NCT04285229, both of which were approved by ethical review boards and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment in COAST-V and NCT04285229. No additional ethical approval or informed consent was required for this secondary analysis of anonymised data.
